Oramed Pharmaceuticals Inc. (ORMP): Price and Financial Metrics


Oramed Pharmaceuticals Inc. (ORMP)

Today's Latest Price: $4.31 USD

0.13 (-2.93%)

Updated Jan 20 6:55pm

Add ORMP to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 484 in Biotech

See all "A" rated Strong Buy stocks

ORMP Stock Summary

  • The ratio of debt to operating expenses for Oramed Pharmaceuticals Inc is higher than it is for about just 7.04% of US stocks.
  • ORMP's price/sales ratio is 42.4; that's higher than the P/S ratio of 93.78% of US stocks.
  • With a year-over-year growth in debt of 503.77%, Oramed Pharmaceuticals Inc's debt growth rate surpasses 96.4% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to Oramed Pharmaceuticals Inc, a group of peers worth examining would be SYBX, CDTX, CBIO, VBLT, and MTEM.
  • Visit ORMP's SEC page to see the company's official filings. To visit the company's web site, go to www.oramed.com.

ORMP Stock Price Chart Interactive Chart >

Price chart for ORMP

ORMP Price/Volume Stats

Current price $4.31 52-week high $5.71
Prev. close $4.44 52-week low $2.40
Day low $4.24 Volume 230,200
Day high $4.41 Avg. volume 174,092
50-day MA $3.86 Dividend yield N/A
200-day MA $3.43 Market Cap 114.91M

Oramed Pharmaceuticals Inc. (ORMP) Company Bio


Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. The company was founded in 2002 and is based in Jerusalem, Israel.


ORMP Latest News Stream


Event/Time News Detail
Loading, please wait...

ORMP Latest Social Stream


Loading social stream, please wait...

View Full ORMP Social Stream

Latest ORMP News From Around the Web

Below are the latest news stories about Oramed Pharmaceuticals Inc that investors may wish to consider to help them evaluate ORMP as an investment opportunity.

We're Hopeful That Oramed Pharmaceuticals (NASDAQ:ORMP) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | January 8, 2021

Oramed to Present at H.C. Wainwright BioConnect 2021 Conference

NEW YORK, Jan. 7, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that CEO Nadav Kidron will present a company overview at the H….

PR Newswire | January 7, 2021

Oramed's obesity drug candidate shows decrease in glucose levels

Oramed Pharmaceuticals ([[ORMP]] +1.6%) has announced results from a proof-of-concept study evaluating its oral leptin drug candidate's safety and pharmacodynamics (glucagon and glucose reduction) in type 1 diabetic patients.Ten patients were enrolled, with 7 randomized to receive one capsule of leptin and 3 randomized to receive a placebo.The study showed...

Seeking Alpha | December 23, 2020

Oramed Reports Positive First in Human Data from Oral Leptin Study

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today results from a proof-of-concept study approved by Israel's Ministry of Health for its oral leptin drug candidate. The single dose study evaluated oral leptin's safety and pharmacodynamics (glucagon and glucose reduction) in type 1 diabetic (T1DM) patients.

Yahoo | December 23, 2020

ORMP: ORMD-0801 in Phase 3 TD2 and NASH Clinical Studies

By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Oramed Pharmaceuticals Inc. (NASDAQ:ORMP), a clinical-stage pharmaceutical company with a proprietary oral protein delivery platform technology, has screened the first patients in its global TD2 Phase 3 trials and its global NASH trial for its proprietary oral insulin capsule, ORMD-0801, the company's lead development candidate. The

Yahoo | December 10, 2020

Read More 'ORMP' Stories Here

ORMP Price Returns

1-mo -3.58%
3-mo 69.02%
6-mo 6.42%
1-year -20.33%
3-year -49.83%
5-year -33.07%
YTD 1.65%
2020 -17.67%
2019 71.67%
2018 -66.67%
2017 47.06%
2016 -28.42%

Continue Researching ORMP

Want to see what other sources are saying about Oramed Pharmaceuticals Inc's financials and stock price? Try the links below:

Oramed Pharmaceuticals Inc (ORMP) Stock Price | Nasdaq
Oramed Pharmaceuticals Inc (ORMP) Stock Quote, History and News - Yahoo Finance
Oramed Pharmaceuticals Inc (ORMP) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9367 seconds.